Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Moodys
Citi
McKesson
Harvard Business School
Argus Health
Cantor Fitzgerald
Dow
Colorcon

Generated: June 22, 2018

DrugPatentWatch Database Preview

EXELON Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Exelon, and what generic alternatives are available?

Exelon is a drug marketed by Novartis and is included in three NDAs. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has thirty-seven patent family members in twenty-seven countries.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Drug patent expirations by year for EXELON
Pharmacology for EXELON
Medical Subject Heading (MeSH) Categories for EXELON
Synonyms for EXELON
(R)-Rivastigmine (Rivastigmine EP Impurity D)
(S)-1-(3-((ethyl(methyl)carbamoyl)oxy)phenyl)-N,N-dimethylethanamine
(S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
(S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methyl-carbamate
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
[3-[(1S)-1-dimethylaminoethyl]phenyl] N-ethyl-N-methylcarbamate
101R548
123441-03-2
2,3-dihydroxybutanedioic acid; 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl N-methyl carbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
AB01275472_02
AB01275472_03
AB01275472-01
AB1004572
ABP001082
AC-8250
AC1L2U92
AJ-08211
AK161672
AKOS015896334
AN-1074
API0008913
BC225687
BDBM10620
BDBM11682
BIDD:GT0316
C-23825
C11766
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-
CC-34273
CCG-221197
CHEBI:8874
CHEMBL636
CS-0946
D03822
D0WY5Q
DB00989
DR000673
DTXSID7023564
EBD46209
ENA 713 free base
ENA-713
Ethyl-methyl-carbamic acid 3-((R)-1-dimethylamino-ethyl)-phenyl ester
Ethyl-methyl-carbamic acid 3-((S)-1-dimethylamino-ethyl)-phenyl ester
Ethyl-methyl-carbamic acid 3-(1-dimethylamino-ethyl)-phenyl ester
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon Patch
Exelon; Rivastigmine hydrogen tartrate; 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylc
F10108
FT-0651952
GTPL6602
HMS2089H18
HY-17368
I06-2037
KS-00000H18
LS-172571
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
MFCD00871496
MLS003876822
MolPort-003-666-662
NCGC00167531-03
Nimvastid
OR210090
PKI06M3IW0
Prometax
Prometax (TN)
rivastigmine
Rivastigmine (JAN/USAN/INN)
Rivastigmine (transdermal patch)
Rivastigmine [USAN:INN:BAN:JAN]
Rivastigmine [USAN:INN]
rivastigmine hexal
Rivastigmine Teva
Rivastigmine Transdermal System
Rivastigmine.tartrate
RL06150
S-Rivastigmine
S4687
SCHEMBL2764
SDZ 212-713
SDZ-212-713
SDZ-ENA-713
SMR002203623
ST24049123
UNII-PKI06M3IW0
W-200966
W-5183
XSVMFMHYUFZWBK-NSHDSACASA-N
Y9059
ZINC4413

US Patents and Regulatory Information for EXELON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for EXELON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-004 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-005 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EXELON
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Transdermal System Extended-release 13.3 mg/24 hr ➤ Subscribe 2013-01-22
➤ Subscribe Transdermal System Extended-release 4.6 mg/24 hr and 9.5 mg/24 hr ➤ Subscribe 2011-04-27
➤ Subscribe Oral Solution 2 mg/mL ➤ Subscribe 2004-11-05
➤ Subscribe Capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg ➤ Subscribe 2004-04-21

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for EXELON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0038 Belgium ➤ Try a Free Trial PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731
C/GB98/041 United Kingdom ➤ Try a Free Trial PRODUCT NAME: RIVASTIGMINE, AS FREE BASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5427501 19970731; CH 5427502 19970731; CH 5427503 19970731; CH 5427504 19970731; CH 5427505 19970731; CH 5427506 19970731; UK EU/1/98/066/001 19980512; UK EU/1/98/066/002 19980512; UK EU/1/98/066/003 19980512; UK EU/1/98/066/004 19980512; UK EU/1/98/066/005 19980512; UK EU/1/98/066/006 19980512; UK EU/1/98/092/023 19980512; UK EU/1/98/092/024 19980512; UK EU/1/98/092/025 19980512; UK EU/1/98/092/026 19980512; UK EU/1/98/066/025 19980512; UK EU/1/98/066/026 19980512; UK EU/1/98/092/019 19980512; UK EU/1/98/092/020 19980512; UK EU/1/98/092/021 19980512; UK EU/1/98/092/022 19980512; UK EU/1/98/0
80031 Netherlands ➤ Try a Free Trial PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cipla
Chinese Patent Office
Mallinckrodt
Express Scripts
Healthtrust
Citi
Chubb
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.